



January 27, 2012

**For Immediate Release**

Company name Otsuka Holdings Co., Ltd.  
 Representative Tatsuo Higuchi  
 President and Representative Director, CEO  
 Code number 4578 First Section , Tokyo Stock Exchange  
 Inquiries Takuma Kimura  
 Director, Investors Relations Department

**Otsuka announces 2011 fourth quarter U.S. net sales figures of ABILIFY®**

Tokyo Japan – Otsuka Holdings Co., Ltd. (Head office: Chiyoda-ku, Tokyo, Japan; President and Representative Director, CEO: Tatsuo Higuchi, "Otsuka Holdings") announces 2011 fourth quarter U.S. net sales <sup>\*1</sup> figures of ABILIFY (aripiprazole), the antipsychotic agent discovered and marketed worldwide by its wholly owned direct subsidiary Otsuka Pharmaceutical Co., Ltd. ("Otsuka Pharmaceutical"). The results follow Bristol-Myers Squibb Company's ("Bristol-Myers Squibb") results announcement for the full year and fourth quarter on Thursday, January 26, 2012.

<sup>\*1</sup> Net sales in U.S. and Puerto Rico

ABILIFY is co-promoted in the U.S. by Otsuka America Pharmaceutical, Inc. ("OAPI," a wholly owned subsidiary of Otsuka Pharmaceutical) and Bristol-Myers Squibb. Net sales of ABILIFY is reported to OAPI; Otsuka Pharmaceutical pays BMS a fee based on the collaboration agreement. 2011 fourth quarter U.S. net sales of ABILIFY reported to OAPI is \$1,076 million.

**【OAPI U.S. Net Sales Figure of ABILIFY】**

(\$ in millions)	1 <sup>st</sup> Qtr	2 <sup>nd</sup> Qtr	3 <sup>rd</sup> Qtr	4 <sup>th</sup> Qtr	Year
2011	897	1,005	983	1,076*	3,960*
% change	6.4%	14.2%	18.3%	12.2%	12.7%
2010	843	880	831	959	3,512
% change	13.3%	6.0%	0.0%	6.9%	6.3%

\* unaudited

The consolidated business forecast announced by the Company on November 10, 2011 will not be changed.

**About ABILIFY:**

Discovered by Otsuka Pharmaceutical Co., Ltd. and jointly developed and commercialized by Otsuka and Bristol-Myers Squibb, ABILIFY is the first and only available dopamine partial agonist and is indicated for the treatment of multiple neurological disorders.

To date, ABILIFY is sold in 65 countries and regions worldwide including Japan with global sales of approximately 370 billion yen in fiscal 2010 accounting for 33.6% of Otsuka Holding's consolidated results.

**About Otsuka Group:**

The Otsuka Group is a diversified healthcare group operating globally under the corporate philosophy "Otsuka-people creating new products for better health worldwide". The Otsuka Group has business operations in 23 countries and regions around the world, and its consolidated sales for fiscal 2010 is ¥1,090.2 billion.